341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)

341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)

Bibliographic Details
Main Authors: Lawrence Karsh, Sreenivas Adurthi, Rahul Aggarwal, Mark Linch, Dan Costin, Jingsong Zhang, Paul Monk, Stefani Corsi-Travali, Adedayo Adedoyin
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items